PharmAla License Agreement and Share-Settlement Liability |
9 Months Ended | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | ||||||||||||||||||||||||||
| Pharmala License Agreement And Share-settlement Liability | ||||||||||||||||||||||||||
| PharmAla License Agreement and Share-Settlement Liability |
On July 20, 2026, Jupiter Neurosciences, Inc. (the “Company”) entered into a Strategic Asset License Agreement (the “License Agreement”) with PharmAla Biotech Holdings Inc. (“PharmAla”), pursuant to which the Company acquired exclusive rights to develop, manufacture and commercialize ALA-002, a proprietary investigational MDMA-based drug candidate, in the United States, including its territories, possessions and commonwealths, including Puerto Rico. The License Agreement was executed on July 20, 2026 and became effective on July 21, 2026, following satisfaction of the specified conditions precedent, including payment of the initial cash consideration and release of the escrow deposit to PharmAla.
Pursuant to the License Agreement, the Company agreed to pay upfront consideration consisting of $1,500,000 in cash and $1,833,333 in common stock consideration, subject to certain contractual pricing adjustments and settlement provisions. The cash consideration included an escrow deposit of $600,000 made on May 19, 2026, and an additional payment of $900,000 upon effectiveness of the License Agreement on July 21, 2026.
To satisfy the common stock consideration of $1,833,333, the Company must issue shares of common stock or pay the common stock consideration in cash. On August 20, 2026, the Company issued shares of common stock to PharmAla in partial satisfaction and has a remaining share issuance liability of shares of common stock or a $ cash obligation. The Company may settle the common stock consideration in cash at its option and must do so if it cannot issue the remining shares, which would require shareholder approval.
The Company determined that the acquired license rights relate to in-process research and development activities and were determined to have no alternative future use at the acquisition date. Accordingly, pursuant to ASC 730, Research and Development, the Company recorded the acquisition cost attributable to the license as research and development expense.
Accounting for Share-Settlement Obligation
The equity consideration under the License Agreement was initially determined based on a contractualy defined volume-weighted average price (“VWAP”) of the Company’s common stock and was subject to a subsequent VWAP reset, as defined. The License Agreement also contains an exchange cap of 19.99% as required by Nasdaq restricting the issuance of shares above specified thresholds without shareholder approval. If the required shareholder approval is not obtained within the contractually prescribed period, the Company may be required to settle the affected consideration in cash.
The Company evaluated the share-settlement obligation for liability or equity classification under ASC 480, Distinguishing Liabilities from Equity, and ASC 815-40, Contracts in Entity’s Own Equity. Because the License Agreement includes an exchange cap and provisions that may require cash settlement if the necessary shareholder approval is not obtained, the Company determined that share settlement was not entirely within its control. Accordingly, the obligation did not meet the requirements for equity classification under ASC 815-40, and is classified as a liability and measured at fair value, which the Company determined to be the cash settlement value of the remaining obligation under the License Agreement.
Initial Recognition and Subsequent Fair Value Measurement
Upon effectiveness of the License Agreement on July 21, 2026, the Company initially recognized a share-settlement obligation of $1,833,333.
On August 20, 2026, the Company issued shares of common stock to PharmAla in partial satisfaction of $889,478 of the equity consideration. Following the determination of the VWAP reset on August 27, 2026, the total number of shares required under the License Agreement became fixed at shares, of which the obligation to issue shares remains outstanding. The final contractual reset price was $ per share. The Company remeasured the outstanding share-settlement liability to fair value as of the reset date, resulting in a $114,691 loss, presented within Loss on change in fair value of license consideration payable in the accompanying unaudited condensed statements of operations.
As of September 30, 2026, the Company remeasured the remaining obligation to fair value, which it determined to be the cash value of the remaining obligation, or $1,058,546. The Company intends to settle the obligation through the issuance of common stock as contemplated in the license agreement, however, the issuance of the remaining share obligation is subject to a shareholder approval, and there can be no assurance that approval is obtained.
The Company classified the fair value measurement within Level III of the fair value hierarchy under ASC 820, based on the observability of the significant inputs used in the valuation.
The following table summarizes the activity in the PharmAla share-settlement liability during the three months ended September 30, 2026:
|
|||||||||||||||||||||||||